维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Cory Higley"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in postliver transplant patients with previous direct-acting antiviral failure:Six case reports显示文摘BACKGROUND Direct-acting antiviral(DAA)therapy regimens are highly effective at eliminating hepatitis C virus(HCV)infection but rates of sustained virologic response(SVR)are lower in patients with decompensated cirrhosis or hepatocellular carcinoma.Since many of these patients will be referred for liver transplant,they will require retreatment after transplantation.Sofosbuvir/velpatasvir/voxilaprevir(SOF/VEL/VOX)is recommended by guidelines as the preferred regimen to treat HCV in DAA-experienced patients following liver transplant however there is limited data.CASE SUMMARY We present the cases of six liver transplant recipients who had previous treatment failure with sofosbuvir-based DAA therapy prior to transplantation and who then received SOF/VEL/VOX after transplant.CONCLUSION This case series demonstrate the real-world efficacy and safety of SOF/VEL/VOX in the post liver transplant setting.Treatment was successful with all patients achieving SVR,it was well tolerated,and there were minimal drug-drug interactions with their immunosuppressants.	Cory Higley Christine C Hsu Coleman Smith Sandeep Nadella Alexander T.Lalos	2020	World Journal of Hepatology2020，12，12：	2

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费